DOCK2 and pneumonia: A risk allele associated with decreased DOCK2 expression is seen in patients with severe COVID-19, and inhibition of DOCK2 with the small molecule inhibitor CPYPP increased pneumonia severity in a hamster model of SARS-CoV-2 infection (28).